Best Supplements to Take With NMNH

NMNH Demands More From Your Methyl Groups Than Its Siblings Do

Most people taking a NAD+ precursor are taking NMN or nicotinamide riboside. NMNH is different in a way that changes what support it needs.

NAD+ metabolism generates nicotinamide as a byproduct, and the body has one way to dispose of it: it methylates it, stamps a methyl group onto the molecule, and excretes it. Every NAD+ precursor creates this methyl demand to some degree. What makes NMNH distinct is how much more potent it is as a precursor. Where NMN must pass through a rate-limiting enzyme called NAMPT before entering the NAD+ biosynthesis pathway, NMNH skips that step entirely and is processed directly by a different enzyme family called NMNAT. Preclinical research shows this bypass produces a substantially greater rise in cellular NAD+ than the same amount of NMN, and sustains that elevation for longer. More NAD+ throughput means more nicotinamide byproduct, which means a higher and more sustained demand on the methylation system that handles it.

There is a secondary pharmacological action that none of NMNH's siblings share: NMNH actually inhibits NAMPT. While it is boosting NAD+ through its own direct pathway, it simultaneously suppresses the endogenous production of NMN from nicotinamide. This combination of a new NAD+ supply route and a partial throttle on the old one is unique to NMNH within the NAD+ precursor family.

NMNH also directly elevates NADH, the reduced electron-carrying form of the molecule, whereas NMN, NR, and nicotinamide primarily raise NAD+ in its oxidized form. The distinction matters for what happens downstream in the mitochondria: NADH is the molecule that donates electrons to the energy-production chain. A direct NADH elevation is a different metabolic stimulus than a NAD+ elevation, and it is one that demands a functioning electron transport chain with adequate cofactors to extract ATP from those electrons.

All of this adds up to a compound that runs hotter than its siblings, in a specific metabolic sense: more NAD+ turnover, more methyl consumption, more demand on the enzyme systems that handle what it produces. The supplements that earn a place in this stack are the ones that either supply what that throughput consumes, operate the machinery it feeds, or protect the NAD+ pool from being dismantled almost as fast as NMNH builds it up.

The Supplements That Matter Most on NMNH

There are no dose numbers on this page. The right amount of each of these depends on your actual NMNH protocol, your current bloodwork, and what else you are already taking. What works as a general reference for one person may be too much or too little for another. MyPeptidePal works out the personalized amounts.

What NMNH Cannot Do Without

NMNH is a metabolic substrate, and substrates do not work in isolation. They get processed by enzymes, and those enzymes require cofactors to function. The four supplements in this section are not optional extras for the ambitious optimizer. They are the raw materials and operating conditions the NMNH-to-NAD+ conversion physically requires.

TMG

TMG, also called trimethylglycine or betaine, is the double-duty pick on this stack, and it earns that designation in a specific and concrete way.

When NAD+ is synthesized and then broken down, nicotinamide is released as a byproduct. The body has to methylate that nicotinamide, adding a methyl group to prepare it for excretion, before it can clear the compound from circulation. Methylation is a chemical process the body runs on a finite daily supply of methyl groups, and when demand increases, supply can fall short. The downstream consequence of methyl depletion is a rise in homocysteine, an amino acid that accumulates when the methylation pathways backing up behind the bottleneck cannot clear it.

TMG donates methyl groups through a pathway involving an enzyme called betaine-homocysteine methyltransferase. It works quickly and efficiently, replenishing the methyl pool that NAD+ metabolism is drawing from. This keeps the excretion pathway running and prevents homocysteine from rising.

Here is the second job it does, which is why it is marked double duty. The methylation-related mood and energy dip that some people notice after starting an NAD+ precursor, a kind of flatness or low-level irritability that appears a few days in, is a sign that methyl groups are being depleted faster than the body is replacing them. TMG heads this off before it starts. It is not treating a rare side effect; it is addressing a predictable metabolic consequence of running NMNH's pathway harder than its siblings do.

Because NMNH drives greater NAD+ throughput than NMN, the methyl demand it creates is proportionally higher. Without TMG, the methylation system eventually becomes the ceiling on how long NMNH can run cleanly.

Homocysteine is a trackable marker. If you are running NMNH without TMG and your homocysteine climbs, that is the methylation drain showing up in your bloodwork.

Magnesium

Magnesium is where the NMNH story depends on chemistry that is easy to overlook.

NMNH does not become NAD+ on its own. It is converted by a family of enzymes called NMNAT, short for nicotinamide mononucleotide adenylyltransferase. These enzymes catalyze the reaction that turns NMNH into NAD+, and they require magnesium ions to do it. Magnesium stabilizes the phosphate groups involved in the NMNAT reaction. Without it, the enzyme's catalytic efficiency drops.

The practical consequence is straightforward: if your body is low on magnesium, the very enzyme that converts NMNH into the molecule you are paying for cannot work at full speed. You are taking NMNH and getting a fraction of the NAD+ output the dose should produce.

Magnesium is one of the most widespread nutritional shortfalls in adults, but standard bloodwork misses it almost entirely. Serum magnesium, which is what most blood panels measure, reflects less than one percent of the body's actual magnesium stores. The body tightly defends serum levels even as intracellular stores fall, so a normal serum reading tells you almost nothing about whether your NMNAT enzymes have adequate cofactor. The marker that actually answers that question is RBC magnesium, which measures the amount of magnesium inside red blood cells and is a reliable proxy for tissue stores.

There is a second reason magnesium matters on this stack: it is required for vitamin D activation. Low magnesium impairs the conversion of vitamin D to its active form in the liver and kidneys, creating a compounding bottleneck when both are low. The two deficiencies interact, which is why magnesium is the first correction to address when either is flagged.

The glycinate form of magnesium is better tolerated than the oxide form, which is poorly absorbed and causes loose stools at higher doses.

Vitamin D3

Vitamin D's place in this stack is downstream of the conversion step itself, but it shapes whether NMNH's output actually translates into usable energy.

NMNH elevates NADH, and those electrons travel into the mitochondrial energy production chain to generate ATP. Vitamin D, through its receptor inside the cell nucleus, signals mitochondria to maintain their energy output. Low vitamin D reduces the efficiency of that mitochondrial process, and that reduction sits directly in the pathway NMNH is feeding. You can raise NADH with NMNH and still lose a meaningful fraction of the resulting ATP because the downstream machinery is running underprovisioned.

The connection to magnesium is direct enough to state explicitly: vitamin D depends on magnesium for its activation in the liver and kidneys, and magnesium absorption is supported by adequate vitamin D. The two nutrients are in a circular dependency, and both are common shortfalls. Testing RBC magnesium alongside 25-OH-D, the standard circulating form of vitamin D measured in bloodwork, gives you the picture on both at once.

On the K2 pairing: extended vitamin D3 supplementation at higher doses raises calcium absorption. Vitamin K2 directs that calcium into bones and away from soft tissue, including blood vessel walls. Pairing K2 with D3 is standard practice for this reason, and it is why the two appear together in this stack.

Riboflavin

Riboflavin, also called vitamin B2, is frequently missing from NAD+ supplement stacks and rarely explained when it appears. The mechanism is specific to how NMNH is processed.

NMNH is handled by a category of enzymes called flavoprotein oxidoreductases. These enzymes carry functional groups known as FAD and FMN, which are the active molecular forms of riboflavin, built directly into the enzyme's structure. FAD and FMN are not made from scratch in the body; they are synthesized from dietary riboflavin. When riboflavin is low, FAD and FMN production falls, and the flavoprotein enzymes that process NMNH cannot maintain their activity.

This is a cofactor role in the strict sense: riboflavin is not doing the same job as NMNAT, but it is required for the functional integrity of the enzyme family that handles NMNH before and alongside that conversion. Riboflavin deficiency does not produce a single dramatic clinical sign, which is part of why it goes undetected. It surfaces as a diffuse reduction in metabolic efficiency.

The evidence for riboflavin's role here is mechanistic and supported by established biochemistry rather than a human trial specifically examining NMNH. That is an honest account of where this one sits: the pathway is understood, the cofactor role is not in dispute, and the direct human trial data on riboflavin combined with NMNH does not exist as of 2026.

Amplifying What NMNH Builds

NMNH raises NAD+ and NADH. The three supplements in this section do not repeat that work. They either use what NMNH produces, or they protect the NAD+ pool from the enzymes that would otherwise dismantle it. Each operates through a genuinely distinct mechanism.

Resveratrol

Resveratrol's connection to NAD+ precursors rests on a family of enzymes called sirtuins. Sirtuins regulate a broad range of cellular processes including DNA repair, the production of new mitochondria, and the expression of genes involved in metabolic efficiency. They are active regulators that can only do their job when NAD+ is available as their fuel.

Resveratrol activates SIRT1, the most studied member of the sirtuin family. NMNH raises the NAD+ that SIRT1 runs on. The two mechanisms are complementary in a precise way: resveratrol increases how much the enzyme does, and NMNH increases how much fuel it has to do it with. Taken with dietary fat, resveratrol's absorption improves substantially, which is the basis for the food co-administration recommendation.

The evidence picture is worth stating honestly. Resveratrol has been studied in human clinical trials for metabolic outcomes including glucose regulation and cardiovascular markers. Its sirtuin activation in human cells is supported by mechanistic research. The human trial evidence for longevity outcomes specifically is mixed, and the combination of resveratrol with NMNH has not been studied in a controlled human trial as of 2026. The synergy argument is sound in mechanism and widely applied in community protocols, but it is not backed by a direct human study of this specific pairing.

Pterostilbene, a close structural relative of resveratrol, appears in some NAD+ stacks as an alternative with somewhat better bioavailability. The mechanism is the same; the evidence base is thinner still.

Apigenin

Apigenin is the highest-value single pick in this section, and that claim rests on one specific fact about NAD+ metabolism: the enzyme CD38 is extremely efficient at degrading NAD+. CD38 cleaves NAD+ as part of its normal cellular function, and its activity increases with age. The result is a NAD+ drain that runs in parallel with whatever your precursor supplement is building.

If NMNH is filling the NAD+ pool and CD38 is simultaneously draining it, the steady-state NAD+ level you reach is lower than it would be if only one of those processes were operating. Apigenin inhibits CD38, slowing the drain. This makes it both a synergist, because it amplifies the NAD+ level NMNH reaches, and a result-preservation supplement, because it maintains that level over time. One supplement doing both jobs is the definition of a high-value stack addition.

Apigenin is found in high concentrations in chamomile, parsley, and celery, but the amounts in food are too low to produce a meaningful CD38-inhibiting effect. The supplement form is what this stack refers to.

The evidence here is community-reported and mechanistic rather than drawn from controlled human trials of apigenin combined with NMNH. The CD38 inhibition mechanism is established in biochemistry. The human-outcome data on apigenin supplementation for NAD+ preservation specifically does not exist at the clinical trial level as of 2026. That is an honest description of where this sits, and it is worth knowing before deciding whether it earns a slot in your stack.

Because apigenin works at both the synergist and result-preservation levels, it appears once in this article, here, under synergists. There is no separate result-preservation section, because apigenin is the only supplement assigned to that lever and its mechanism is fully covered here.

CoQ10

CoQ10, also called coenzyme Q10, is an electron carrier that operates inside the mitochondrial inner membrane. Its job is to transport electrons from the early steps of the energy-production chain to the later ones, and that transport is what allows the mitochondria to produce ATP efficiently.

NMNH elevates NADH, the molecule that donates electrons into the start of that chain. If CoQ10 is low, the electrons NMNH generates stack up at an earlier step and cannot be processed. ATP output falls not because the fuel is missing but because the transport system is a bottleneck. NMNH providing the electron input and CoQ10 ensuring those electrons move through the chain support end-to-end mitochondrial energy production in a way that neither achieves as well without the other.

A practical note on form: CoQ10 exists in two forms, ubiquinone (the oxidized form) and ubiquinol (the reduced form). Ubiquinol is better absorbed, particularly in adults over 40, and is the preferred form for this stack. The evidence for CoQ10 in mitochondrial support is clinical in populations with demonstrated mitochondrial dysfunction. Its synergy with NMNH specifically is mechanistic and community-reported rather than supported by a controlled trial as of 2026.

One specific interaction worth calling out: statins, the cholesterol-lowering medications, deplete CoQ10 as a consequence of how they work. Anyone on statin therapy running an NMNH stack has a concrete, pharmacological reason to treat CoQ10 as a priority rather than an optional addition.

Cautions and Interactions

Three medications require physician consultation before running NMNH

These are not advisory cautions. Each of the three warrants a conversation with a prescriber before NMNH is started.

Insulin and glucose-lowering medications. NMNH may alter insulin signaling and blood glucose regulation through downstream NAD+-dependent pathways involving sirtuins and PARP enzymes, which play a role in cellular energy and stress signaling. In individuals already on insulin or metformin, the combined effect on blood sugar can push glucose lower than intended, creating a hypoglycemia risk that is difficult to predict without monitoring. This requires prescriber oversight, not a supplement timing adjustment.

Warfarin and anticoagulants. NAD+ precursors in the nicotinamide class are often described as interacting with the enzymes that metabolize anticoagulants, but that description does not hold up. No human study shows any NAD+ precursor meaningfully altering warfarin clearance, and no published case report describes one changing INR, the measure of how fast blood clots. The one documented signal in the wider vitamin B3 family involves high-dose extended-release nicotinic acid, a different compound, acting through a mechanism unrelated to those enzymes. NMNH itself is barely studied in humans at all, which is the more honest reason for caution here: the absence of an established interaction is not the same as evidence of safety. Anyone on warfarin or any other anticoagulant should discuss NMNH with the prescriber managing that medication before starting it.

Cytotoxic chemotherapy agents. NAD+ plays a role in the energy metabolism of cancer cells as well as healthy ones. NAD+ supplementation may either fuel tumor metabolism or antagonize drugs designed to work by depleting NAD+. This is classified as contraindicated without specific oncologist approval.

Do not stack NMNH with other NAD+ precursors

NMN, NR, and niacin should not be combined with NMNH. The pathways overlap substantially, the combined dose does not produce additive benefit, and the side-effect burden, particularly nausea and flushing, increases without a corresponding improvement in outcome. This applies especially to niacin, which relies on the NAMPT-dependent pathway that NMNH's bypass makes unnecessary.

Blood pressure medications

Some evidence suggests caution when combining NMNH with antihypertensive medications, though the mechanism is not as well characterized as the glucose or anticoagulant interactions. If you are on blood pressure medication, flag the NMNH addition with your prescriber before starting.

Populations that should not use NMNH without medical supervision

No safety data exists for NMNH in pregnancy or breastfeeding, and both are contraindicated. Individuals with liver or kidney disease face an unestablished safety profile because both organs are involved in NMNH's metabolic handling. Use in these populations requires physician supervision.

Frequently Asked Questions

How much of each supplement should I take with NMNH?

There are no dose amounts on this page, and that is intentional rather than an oversight. The right amount of TMG, magnesium, CoQ10, and the rest depends on your current NMNH protocol, what your bloodwork shows for homocysteine, RBC magnesium, and 25-OH-D, and what else you are already taking. MyPeptidePal builds a personalized plan from those inputs rather than printing a number that fits almost no one precisely.

Which blood markers actually matter when running NMNH?

Homocysteine is the most NMNH-specific marker to watch: a rising homocysteine tells you that methyl group demand is outpacing supply, which is the drain that TMG addresses. RBC magnesium tells you whether the NMNAT conversion enzyme has adequate cofactor. 25-OH-D tells you whether the mitochondrial downstream of NMNH's output is provisioned. Fasting glucose matters if you are on any medication for blood sugar, because the interaction in that category is classified as serious.

Do any of these supplements interfere with how NMNH works?

None of the supplements in this stack antagonize NMNH's mechanism. The caution runs in the other direction: other NAD+ precursors like NMN, NR, and niacin should not be added to the stack, because their pathways overlap with NMNH without producing additive benefit and they increase the side-effect load. The supplements here, TMG, magnesium, resveratrol, CoQ10, and the others, either support the conversion step, operate downstream of what NMNH produces, or protect the NAD+ pool. None of them compete with it.

Can I take NMNH in the evening instead?

Taking NMNH late in the day reliably disrupts sleep for a proportion of users, because NAD+ signaling interacts with the biology of circadian rhythms. The morning-only recommendation is not arbitrary. The fat-soluble supplements in this stack, vitamin D3 and CoQ10 in particular, are most efficiently absorbed alongside a meal, which makes the morning dose with breakfast the natural and practical time for the full stack.

Do I need to keep taking these supplements after I stop NMNH?

The cofactors in this stack, TMG, magnesium, vitamin D3, and riboflavin, address nutritional needs that exist independently of NMNH. If your RBC magnesium or 25-OH-D were low before you started, stopping NMNH does not resolve those shortfalls; they warrant ongoing attention regardless. TMG's methyl-donor role is most relevant while NAD+ throughput is elevated, so its urgency decreases when NMNH is stopped. Resveratrol, apigenin, and CoQ10 each have rationales for general use that sit outside the NMNH context entirely.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of NMNH and the nutrients that support it in one place.